Proceedings of the 2013 CINP summit: innovative partnerships to accelerate CNS drug discovery for improved patient care.

Central nervous system (CNS) diseases and, in particular, mental health disorders, are becoming recognized as the health challenge of the 21(st) century. Currently, at least 10% of the global population is affected by a mental health disorder, a figure that is set to increase year on year. Meanwhile, the rate of development of new CNS drugs has not increased for many years, despite unprecedented levels of investment.

Securing the future of drug discovery for central nervous system disorders.

Innovative partnerships among researchers, patients, regulators, payors and industry are needed to reinvigorate drug discovery for central nervous system disorders. Here, we summarize plans of the Collegium Internationale Neuro-Psychopharmacologicum (CINP) to achieve this goal.

Externalizing research through adaptive frameworks.

Adaptive approaches to collaborations between industry and academic research institutions can enable both parties to achieve their goals more effectively. Here, we discuss our experience with such approaches and suggest recommendations for addressing the associated management challenges.